Biomet Spine Sales Lag In Q4; Firm Looks To Differentiated Devices
This article was originally published in The Gray Sheet
Executive Summary
Biomet's spine sales rose just 1% to $62 million last quarter, but the company is confident growth will pick up as it puts more emphasis on "highly differentiated" devices, CEO Jeffrey Binder said during a July 13 call reporting fourth-quarter earnings for Biomet's fiscal year 2010, ended May 31
You may also be interested in...
Hip, Knee Sales Growth Slows In Second Quarter For Top Orthopedic Firms
Overall weakness in the hip-and-knee market resulted in low-single-digit reconstructive sales growth for Zimmer, Stryker and Johnson & Johnson/DePuy in the second quarter
Hip, Knee Sales Growth Slows In Second Quarter For Top Orthopedic Firms
Overall weakness in the hip-and-knee market resulted in low-single-digit reconstructive sales growth for Zimmer, Stryker and Johnson & Johnson/DePuy in the second quarter
Biomet Hip Sales Up Slightly, With Two New Systems Nearing Launch
Biomet hip sales advanced 4% on a constant currency basis in the firm's Feb. 28-ended quarter, but the company expects growth to pick up in the second half of the year after it launches the Archos modular hip revision system and a mobile bearing hip in the U.S